Maurits L van Montfoort
Overview
Explore the profile of Maurits L van Montfoort including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
381
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Downes M, Lajkosz K, Algaba F, Allory Y, Amin M, Cheng L, et al.
Histopathology
. 2025 Mar;
PMID: 40058790
Aims: A hybrid-three tier system with low grade (LG), high grade- G2 (HG-G2), high grade- G3 (HG-G3) has been proposed in recognition of, and to help address, the clinical heterogeneity...
2.
Chelushkin M, van Dorp J, van Wilpe S, Seignette I, Mellema J, Alkemade M, et al.
Clin Cancer Res
. 2024 Jul;
30(18):4227-4239.
PMID: 39047168
Purpose: Platinum-based chemotherapy and immune checkpoint inhibitors are key components of systemic treatment for muscle-invasive and advanced urothelial cancer. The ideal integration of these two treatment modalities remains unclear as...
3.
Gil-Jimenez A, van Dijk N, Vos J, Lubeck Y, van Montfoort M, Peters D, et al.
Nat Commun
. 2024 Mar;
15(1):2538.
PMID: 38514623
Immune checkpoint inhibitors (ICI) can achieve remarkable responses in urothelial cancer (UC), which may depend on tumor microenvironment (TME) characteristics. However, the relationship between the TME, usually characterized by immune...
4.
van Dorp J, Pipinikas C, Suelmann B, Mehra N, van Dijk N, Marsico G, et al.
Nat Med
. 2023 Jul;
30(1):304.
PMID: 37460757
No abstract available.
5.
van Dorp J, Pipinikas C, Suelmann B, Mehra N, van Dijk N, Marsico G, et al.
Nat Med
. 2023 Feb;
29(3):588-592.
PMID: 36732628
Cohort 1 of the phase 1B NABUCCO trial showed high pathological complete response (pCR) rates with preoperative ipilimumab plus nivolumab in stage III urothelial cancer (UC). In cohort 2, the...
6.
Einerhand S, van Dijk N, van Dorp J, de Feijter J, van Montfoort M, van de Kamp M, et al.
Int J Cancer
. 2022 May;
151(11):2004-2011.
PMID: 35603905
Despite treatment with cisplatin-based chemotherapy and surgical resection, clinical outcomes of patients with locally advanced urothelial carcinoma (UC) remain poor. We compared neoadjuvant/induction platinum-based combination chemotherapy (NAIC) with combination immune...
7.
van Dorp J, van Montfoort M, van Dijk N, Hofland I, de Feijter J, Bergman A, et al.
Clin Genitourin Cancer
. 2022 Jan;
20(2):e173-e179.
PMID: 35016887
No abstract available.
8.
van Dijk N, Gil-Jimenez A, Silina K, van Montfoort M, Einerhand S, Jonkman L, et al.
Front Immunol
. 2022 Jan;
12:793964.
PMID: 34987518
Candidate immune biomarkers have been proposed for predicting response to immunotherapy in urothelial cancer (UC). Yet, these biomarkers are imperfect and lack predictive power. A comprehensive overview of the tumor...
9.
Veerman H, Donswijk M, Bekers E, Olde Heuvel J, Bodar Y, Boellaard T, et al.
BJU Int
. 2021 Dec;
129(3):314-317.
PMID: 34854204
No abstract available.
10.
Stokkel L, van Montfoort M, van Boven H, Mertens L, van Rhijn B
Eur Urol Open Sci
. 2021 Oct;
33:56-60.
PMID: 34622223
We report two cases with recurrences of urachal adenocarcinoma (UrAC) in the urethra. Both patients had mucinous UrAC without metastasis, for which they were treated with en-bloc partial cystectomy and...